Results 31 to 40 of about 838,442 (361)
Chronic Myeloid Leukemia: Modern therapies, current challenges and future directions
Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm caused by a reciprocal translocation [t(9;22)(q34;q11.2)] that leads to the fusion of ABL1 gene sequences (9q34) downstream of BCR gene sequences (22q11) and is cytogenetically visible as ...
A. Osman, M. Deininger
semanticscholar +1 more source
Acute myeloid leukemia carrying NPM1 mutations and cytoplasmic nucleophosmin (NPMc+ acute myeloid leukemia) represents one-third of adult AML (50–60% of all acute myeloid leukemia with normal karyotype) and shows distinct biological, pathological and ...
Brunangelo Falini +12 more
doaj +1 more source
Eradication of chronic myeloid leukemia stem cells: a novel mathematical model predicts no therapeutic benefit of adding G-CSF to imatinib [PDF]
Imatinib mesylate induces complete cytogenetic responses in patients with chronic myeloid leukemia (CML), yet many patients have detectable BCR-ABL transcripts in peripheral blood even after prolonged therapy.
Holyoake, T. +14 more
core +1 more source
The role of peptide and DNA vaccines in myeloid leukemia immunotherapy
While chemotherapy and targeted therapy are successful in inducing the remission of myeloid leukemia as acute myeloid leukemia (AML) and chronic myeloid leukemia (CML), the disease remains largely incurable.
Lin Chen, Li Yangqiu
doaj +1 more source
Inhibition of MDR1 does not sensitize primitive chronic myeloid leukemia CD34+ cells to imatinib [PDF]
<p><b>Objective:</b> To investigate the interaction of imatinib mesylate (IM) with the clinically relevant adenosine triphosphate-binding cassette efflux transporter MDR1 (ABCB1) in cells from patients with chronic myeloid leukemia (CML)
Holyoake, T.L. +4 more
core +1 more source
Hypocellular acute myeloid leukemia in adults: analysis of the clinical outcome of 123 patients
Background The hypocellular variant of acute myeloid leukemia accounts for less than 10% of all cases of adult acute myeloid leukemia. It is defined by having less than 20 percent of cellular bone marrow in a biopsy at presentation.
Aref Al-Kali +10 more
doaj +1 more source
The recent identification of DNMT3A mutations in de novo acute myeloid leukemia prompted us to determine their frequency, patterns and clinical impact in a cohort of 98 patients with either therapy-related or secondary acute myeloid leukemia developing ...
Isabella Fried +9 more
doaj +1 more source
Clonal leukemic evolution in myelodysplastic syndromes with TET2 and IDH1/2 mutations
Somatic mutations of TET2, IDH1, and IDH2 have been described in myelodysplastic syndrome. The impact of these mutations on outcome of myelodysplastic syndrome and their progression to secondary acute myeloid leukemia remains unclear.
Tung-Liang Lin +18 more
doaj +1 more source
The indications for allogeneic stem cell transplantation (SCT) in Acute Myeloid Leukemia (AML) represent a real challenge due to the clinical and genetic heterogeneity of the disorder.
Hartwig, Maite +5 more
core +1 more source
Acute myeloid leukemia is a disorder characterized by abnormal differentiation of myeloid cells and a clonal proliferation derived from primitive hematopoietic stem cells.
Dang Wu +13 more
doaj +1 more source

